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Abstract
Anti-cytokine autoantibodies may cause immunodeficiency and have been recently recognized as ‘autoimmune phenocopies 
of primary immunodeficiencies’ and are found in particular, but not exclusively in adult patients. By blocking the cytokine’s 
biological function, patients with anti-cytokine autoantibodies may present with a similar clinical phenotype as the related 
inborn genetic disorders. So far, autoantibodies to interferon (IFN)-γ, GM-CSF, to a group of TH-17 cytokines and to IL-6 
have been found to be causative or closely associated with susceptibility to infection. This review compares infectious dis-
eases associated with anti-cytokine autoantibodies with primary immunodeficiencies affecting similar cytokines or related 
pathways.
Introduction
Genetically defined, primary immunodeficiencies that 
impair specific cytokine pathways cause increased suscep-
tibility for selective infectious diseases, and present mostly 
early in infancy or childhood. Mutations in the cytokine 
itself, its cognate receptor or downstream signaling mol-
ecules may interrupt their biological function, which leads to 
an impaired immune response. Anti-cytokine autoantibodies 
were recognized as phenocopies of primary immunodefi-
ciencies (Tangye et al. 2020), and are found in particular, but 
not exclusively in adult patients. Autoantibodies, produced 
by auto-reactive B cells, may bind to cytokines. In sufficient 
concentration, anti-cytokine autoantibodies could block the 
signaling and neutralize the biological function of target 
cytokines, by preventing the direct binding to its receptor 
and (or) depleting the cytokine through forming a cytokine/
autoantibodies complex (Piccoli et al. 2015). Autoantibodies 
against cytokines are, however, not necessarily associated 
with a respective neutralizing activity (Karner et al. 2016; 
von Stemann et al. 2017). By blocking the cytokine’s bio-
logical function, patients with anti-cytokine autoantibodies 
may present with a similar clinical phenotype as the related 
inborn genetic disorders. Although the exact mechanism 
is largely unknown, the production of autoantibodies may 
require external exposure to cross-reactive antigens and 
multiple steps to break tolerance in the adaptive immune 
response. This may explain why most (but not all) patients 
with anti-cytokine autoantibodies present later in life. So far, 
autoantibodies to interferon (IFN)-γ, GM-CSF, to a group of 
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TH-17 cytokines comprising IL-17A, IL-17F, IL-22, IL-23, 
and to IL-6 have been found to be causative or closely asso-
ciated with susceptibility to infection. In contrast, high levels 
of neutralizing autoantibodies may not cause any expected 
effects in vivo, as, e.g., shown by patients with autoantibod-
ies to type I IFNs (IFNα and IFNω), which do not present 
with increased susceptibility to viral infections (Weiler et al. 
2018). It has been suggested that this may be because of a 
large number of redundant type I IFN species, resulting in 
incomplete neutralization of the overall antiviral activity of 
IFNs by the autoantibodies (Puel et al. 2010).
Anti‑interferon‑γ autoantibodies as an etiology 
in mycobacterial infections in adults
Interferon-γ is a key cytokine produced by activated T cells, 
natural killer cells, and group I innate lymphoid cells. IFN-γ 
receptors are expressed widely on most cell types, but espe-
cially on myeloid cell (such as macrophages and dendritic 
cells). The identification of IFN-γ receptor deficiencies 
(IFNGR1 and IFNGR2) in patients with Mendelian suscep-
tibility to mycobacterial disease (MSMD) demonstrated that 
IFN-γ plays a critical and non-redundant role in control-
ling mycobacterial infections (Rosain et al. 2019). Isolated 
and syndromic MSMD comprises now a group of genetic 
disorders caused by mutations in 16 published genes (see 
Table 1), all of them being involved in IFN-γ-mediated 
immunity, including impaired IFN-γ production (IL12B, 
IL12RB1, IL12RB2, IL23R, IRF8, TYK2, ISG15, IKBKG, 
RORC) or impaired cellular responses to IFN-γ (IFNGR1, 
IFNGR2, JAK1, STAT1, IRF8, CYBB, SPPL2A) (Bustamante 
2020; Martinez-Barricarte et al. 2018; Rosain et al. 2019). 
More recently, inborn IFN-γ deficiency has been reported 
in two patients with mycobacterial infection (Kerner et al. 
2020). Patients with complete loss of IFN-γ activity present 
with early onset, severe, disseminated infections caused by 
low-virulence mycobacteria, such as bacillus Calmette–Gué-
rin (BCG) vaccines and nontuberculous environmental 
mycobacteria (NTM). Some patients with MSMD may also 
develop infections with Mycobacterium tuberculosis, non-
typhoidal salmonella (NTS), candidiasis and symptoms of 
tuberculosis (see Table 1) (Bustamante et al. 2014).
High titers of highly neutralizing anti-IFN-γ autoantibod-
ies (nAIGAs) were initially reported by several groups in 
sporadic patients or small case series with NTM infections 
(Doffinger et al. 2004; Hoflich et al. 2004; Kampmann et al. 
2005; Patel et al. 2005). In recent years, however, larger 
cohorts of nAIGA patients were reported from Southeast 
Asia, with the majority from Thailand, Hong Kong, Tai-
wan and Japan (Aoki et al. 2018; Browne et al. 2012; Chi 
et al. 2013, 2016). Only few of the reported cases did not 
originate from this region (Hanitsch et al. 2015; Kampmann 
et al. 2005; O’Connell et al. 2014; van de Vosse et al. 2017). 
Around 500 patients with nAIGAs have been reported up 
to now in the literature but the exact prevalence rate of 
nAIGAs-related disease is unknown (Aoki et  al. 2018; 
Barcenas-Morales et al. 2016, 2019; Browne 2014; Browne 
et al. 2012; Chi et al. 2013, 2016; Chruewkamlow et al. 
2016; Doffinger et al. 2004; Hoflich et al. 2004; Jutivorakool 
et al. 2018; Kampmann et al. 2005; Patel et al. 2005; Wipasa 
et al. 2018; Wongkulab et al. 2013; Wu et al. 2018).
Similar to patients with MSMD, mycobacterial infections 
are the main clinical presentations for patients with nAIGAs, 
and a considerable proportion of these infections (95%) is 
severe and disseminated (Aoki et al. 2018; Browne et al. 
2012; Chi et al. 2016). Both, slowly-growing and rapidly-
growing NTMs, are isolated from patients with nAIGAs, 
but the distribution of species varies widely and depends on 
the geographical characteristics (Aoki et al. 2018; Browne 
et al. 2012; Chi et al. 2016; Wongkulab et al. 2013). Every 
organ system of the body can be infected by NTM species, 
but lymph nodes, bones/joints, and lungs are the leading 
organ systems affected (Aoki et al. 2018; Browne et al. 2012; 
Chi et al. 2016; Wongkulab et al. 2013). Almost all patients 
are adults in the range from 40 to 70 years with no sex pre-
dominance. However, more recently, two young patients 
presenting at 10 years and 16 years, respectively, have been 
reported (Liew et al. 2019). In addition to NTM infections, 
some nAIGAs patients also were developing Tuberculosis, 
which may precede, be concomitant with, or follow the 
diagnosis of NTM infections (Browne et al. 2012; Chi et al. 
2016; Kampitak et al. 2011). However, the role of nAIGAs 
in the pathogenesis of tuberculosis remains to be elucidated.
Invasive NTS is another unique clinical picture among 
patients with nAIGAs. Among MSMD cases, salmonello-
sis is found in one-third of patients with IL-12/23-related 
defects (IL-12Rβ1 deficiency and IL-12p40 deficiency) 
(Bustamante et al. 2014). In the cases with nAIGAs, a his-
tory of salmonellosis is found in 29–40% of patients, which 
is very similar to the proportion of MSMD patients with 
IL-12/23 defects (Browne et al. 2012; Chi et al. 2016; Wong-
kulab et al. 2013). However, it should be noted that salmo-
nellosis was found in < 10% of patients with IFN-γR1 and 
IFN-γR2 deficiency. It is worth to mention that IL-12-re-
lated inborn deficiencies show an increased susceptibility 
to mycobacterial infections; however, the penetrance is not 
complete. Anti-IL-12 autoantibodies have been reported in 
a few patients without mycobacterial infection (Sim et al. 
2013), which is consistent with the observation of incom-
plete penetrance for MSMD in IL-12 pathway-related 
genetic defects (Fieschi and Casanova 2003). Bacteria other 
than NTS, such as Streptococcus spp., Burkholderia cepacia, 
B. pseudomallei, Staphylococcus aureus, Legionella pneu-
mophila, and Enterobacteriaceae are occasionally isolated 
from the nAIGAs patients (Browne et al. 2012; Chi et al. 
2016; Tang et al. 2010).
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A variety of viral infections have been reported in patients 
with nAIGAs, but varicella-zoster virus (VZV) is the major 
causative agent and presents predominantly as shingles (her-
pes zoster) among this patient population. Most VZV infec-
tions are localized, but occasionally disseminated and severe 
(Browne et al. 2012; Chi et al. 2013, 2016; Jutivorakool et al. 
2018). In contrast to patients with nAIGAs, VZV infections 
are only sporadically reported in patients with IFN-γR1 and 
IFN-γR2 deficiency. There is no clear explanation for these 
differences in the clinical presentations between patients 
with IFN-γR deficiency and patients with nAIGAs, but the 
age of disease onset might partially explain the divergent 
phenotypes between the two patient groups. Patients with 
complete IFN-γR1 and IFN-γR2 deficiency are children and 
may have no chance to expose to VZV during their lifetime; 
therefore, these patients are free from herpes zoster. A few 
cases with nAIGAs have comorbidities, such as diabetes 
mellitus and autoimmune diseases; nevertheless, the major-
ity cases have no sign of autoimmune disease other than the 
nAIGAs (Chi et al. 2016; Doffinger et al. 2004; Hung et al. 
2018; Jutivorakool et al. 2018).
No familial nAIGAs cases have been reported so far; 
however, almost all patients with nAIGAs originate from 
Southeast Asia and Japan, which suggested that genetic 
factor(s) might be involved. HLA class I and class II 
molecular typing showed a strong association of nAIGAs 
and certain HLA class II molecules in Taiwanese patients 
(DRB1*16:02 and DQB1*05:02) (Chi et  al. 2013) and 
patients from other Southeast Asian countries, including 
Thailand, the Philippines, Vietnam, and Laos (DRB1*15:02 
and DQB1*05:01) (Ku et al. 2016), with the DR/DQ haplo-
types being in close vicinity and, therefore, a strong linkage 
disequilibrium in both cases. DRB1*16:02 and DRB1*15:02 
are commonly found in Southeast Asians, Amerindian and 
Pacific Islanders, but rarely found in Caucasians and Afri-
cans (Gonzalez-Galarza et al. 2011; Middleton et al. 2003). 
The detailed mechanism of these risk alleles in autoanti-
bodies production is still unknown. HLA II class molecules 
could present the antigens to CD4 T which guide the B-cell 
activation and maturation. The associations of DRB1*16:02 
and DRB1*15:02 are extremely strong. Therefore, these risk 
alleles might be directly involved in the pathogenic autoan-
tibodies production. However, as only a very small portion 
of these risk alleles carriers have developed nAIGAs, other 
factors, including genetic or environmental factors, are likely 
to be involved. Their identification will be crucial for our 
understanding of this disease.
Antibodies to GM‑CSF are 
associated not only with pulmonary 
alveolar proteinosis (PAP) 
but also with extrapulmonary infections 
and cerebral Cryptococcosis in the absence 
of PAP
GM-CSF is a haematopoietic growth factor which in par-
ticular promotes the development of macrophages, dendritic 
cells and neutrophils. In the lung, it is important for dif-
ferentiation and function of alveolar macrophages. High 
titer, neutralizing autoantibodies against GM-CSF are the 
autoimmune correlate of the much rarer primary GM-CSF-
receptor deficiency causing PAP by impairing the alveolar 
macrophage-mediated surfactant lipid and protein metabo-
lism leading to accumulation and respiratory insufficiency. 
In contrast to anti-IFN-γ autoantibodies, there is no associa-
tion with specific HLA alleles (Anderson et al. 2019).
Patients with autoimmune PAP may present not only with 
opportunistic infection, e.g., by intracellular pathogens such 
as Nocardia and Histoplasma which may be secondary to the 
underlying lung dysfunction but also with extrapulmonary 
diseases caused by Cryptococcus, Nocardia and Aspergil-
lus (Punatar et al. 2012; Trapnell et al. 2019). However, it 
is worth to note that these infections might be secondary 
to impaired lung function by PAP and/or to therapeutic 
immuno-suppression.
Recently, anti-GM-CSF autoantibodies have been found 
in patients with Nocardia infection or cerebral Cryptococcus 
gattii infection (Kuo et al. 2017; Rosen et al. 2013, 2015). 
Cryptococcus neoformans is an environmental opportun-
istic species which causes disease in particular in patients 
infected by human immunodeficiency virus (HIV). However 
interestingly, anti-GM-CSF autoantibodies patients mostly 
suffered from C. gattii, but not from C. neoformans (Kuo 
et al. 2017; Rosen et al. 2013; Saijo et al. 2014b). Despite 
carrying neutralizing autoantibodies to GM-CSF, these 
patients did not manifest PAP at the time of diagnosis, but 
PAP developed in only few cases at a later time point (Demir 
et al. 2018; Punatar et al. 2012; Quah et al. 2018; Rosen et al. 
2013). It is possible that in those patients, the autoantibod-
ies may have only dampened the function of GM-CSF to 
some extent, while still allowing sufficient activity of the 
alveolar macrophages. Piccoli et al. showed that full neu-
tralization needed the synergistic recognition of non-crossre-
active epitopes by multiple anti-GM-CSF clones. This could 
explain the difference between anti-GM-CSF-positive indi-
viduals with and without PAP (Piccoli et al. 2015).
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Autoantibodies against IL‑6 predispose 
to pyogenic infections
Four patients with autoantibodies against IL-6 who devel-
oped severe bacterial infections have been published to date 
(Bloomfield et al. 2019; Nanki et al. 2013; Puel et al. 2008). 
Further, patients with autoantibodies against IL-6 and severe 
bacterial infections have been identified (Doffinger and von 
Bernuth unpublished data). All patients presented with low 
C-reactive protein (CrP) despite severe pyogenic infections. 
In these patients anti-IL-6-auto-antibodies were of high titer 
and neutralized IL-6 (phosphorylation of STAT3 and / or 
production of CrP). A similar susceptibility for pyogenic 
infections has been described in patients with impaired pro-
duction of IL-6 due to defects in MyD88/IRAK/NEMO/
IκBα-dependent signaling or with impaired IL-6-signaling 
due to defects in the IL-6-receptor/gp130/ZNF341/STAT3-
dependent pathway (Beziat et al. 2018, 2020; Courtois et al. 
2003; Doffinger et al. 2001; Frey-Jakobs et al. 2018; Minegi-
shi et al. 2007; Nahum et al. 2019; Picard et al. 2003, 2010; 
Schwerd et al. 2017; Spencer et al. 2019; von Bernuth et al. 
2008). The thorough comparison of the infectious phenotype 
in patients with autoantibodies against IL-6, with impaired 
IL-6 production or with impaired IL-6 signaling reveals 
specific overlaps: Patients with autoantibodies against IL-6, 
with impaired IL-6 signaling and with impaired IL-6 pro-
duction show increased susceptibility for severe pyogenic 
infections, in particular but not exclusively by staphylo-
cocci and pneumococci (Nanki et al. 2013; Picard et al. 
2010; Puel et al. 2008); whereas, increased susceptibility 
to staphylococcal skin infections seems in particular com-
mon in patients with autoantibodies against IL-6 and with 
selectively impaired IL-6 signaling (Nahum et al. 2019; Puel 
et al. 2008; Spencer et al. 2019).
Autoantibodies to TH17 cytokines (IL‑17A/F, 
IL‑22, IL‑23) are associated with chronic 
mucocutaneous candidiasis
Autoantibodies to Th17 cytokines can be found in patients 
suffering from type I Autoimmune polyglandular syndrome 
(APS1) (Bruserud et al. 2016) and thymoma (Wolff et al. 
2014). A common denominator between those conditions 
may be impaired tolerance induction caused by primary 
(in APS1) or secondary structural (in thymoma) disruption 
of thymus function (Barcenas-Morales et al. 2016; Cheng 
and Anderson 2018). In particular, APS1 patients and to 
a lesser degree patients with thymoma may present with 
neutralizing autoantibodies to TH17 cytokines including 
IL-17A/F, IL-22 and IL-12/IL-23, which are associated 
with CMC (Kisand et al. 2010; Puel et al. 2010). APS1 is 
a complex auto-immune syndrome with CMC as its only 
infectious manifestation (Li et al. 2017, 2018). A subset of 
patients with thymoma, a thymic epithelial cancer, may as 
well present with CMC which may be in the context of wider 
infectious complications (Burbelo et al. 2010; Kisand et al. 
2010; Rosenberg et al. 2016). The cytokines IL-17A, IL-
17F, and IL-22 are mainly produced by Th17 cells and play 
an important role in the mucosal defense against Candida 
(Okada et al. 2016). IL-23 is mainly produced by dendritic 
cells and macrophages and is required for the development 
of TH17 cells (Gaffen et al. 2014; Langrish et al. 2004). 
Primary deficiencies in the IL17 axis including IL-17F, 
IL-17RA, IL17RF and the intracellular adaptor ACT1 have 
been found to predispose to CMC (Puel 2020). Patients with 
impaired IL-12/IL-23 signaling show as well an increased 
incidence of CMC (Okada et al. 2016). Surprisingly, how-
ever, patients with IL-23R deficiency were not reported 
with CMC (Martinez-Barricarte et al. 2018). Furthermore, 
CMC is part of the infectious spectrum found in syndromic 
primary deficiencies of CARD9, STAT3, STAT1, RORT, 
ZNF341, and JNK1 which all show diminished Th17 immu-
nity (Beziat et al. 2018; Frey-Jakobs et al. 2018; Li et al. 
2019; Puel 2020).
Concluding remarks
Up to now autoantibodies to four major groups of 
cytokines—IFN-γ, GM-CSF, to a group of TH-17 cytokines 
comprising IL-17A, IL-17F, IL-22, IL-23, and to IL-6—
have been found to be causative or closely associated with 
increased susceptibility to selective infection. The largest 
body of evidence exists for patients with antibodies against 
anti-IFN-γ, as more than 500 patients with predominant sus-
ceptibility to NTM infections and non-typhoid salmonellosis 
are described. This clinical phenotype strongly resembles 
the one of patients with inborn deficiencies of IFN-γ-
production or IFN-γ-response. Similarly, multiple patients 
with autoantibodies against TH-17 cytokines (comprising 
IL-17A, IL-17F, IL-22, IL-23) whose selective susceptibility 
to candidiasis strongly resembles inborn deficiencies with 
impaired production or response to IL-17 were described. 
Autoantibodies against GM-CSF seem to impair the defense 
against a rather broad group of pathogens whose common 
denominator is being controlled by macrophages: Nocardia, 
Histoplasma, Cryptococcus gattii, Aspergillus and maybe 
NTM. Autoantibodies to GM-CSF are also the major cause 
for PAP. Only in this aspect, anti-GM-CSF autoantibodies 
cause the same disease as inborn defects of the GM-CSF 
receptor. It is unknown why inborn defects of the GM-CSF 
receptor do not predispose to infections as do the respec-
tive autoantibodies. Autoantibodies against IL-6 have yet 
been described in only few patients, but seem to predispose 
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to pneumococcal and staphylococcal infections. This selec-
tive susceptibility strikingly resembles inborn defects with 
impaired production of IL-6 or impaired response to IL-6.
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